
Sign up to save your podcasts
Or
Dutch biotech Merus’ EGFR x LGR5 bispecific antibody has caught investors’ attention in the run-up to ASCO as a new approach to block EGFR signaling. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Phase II data from Merus for petosemtamab as they preview the American Society of Clinical Oncology’s upcoming annual meeting. The analysts also assess a setback in a gene therapy trial for Rocket Pharmaceuticals, renewed interest in cancer target EpCAM, and a flurry of biopharma activity on the Hong Kong stock exchange. Finally, the team previews BioCentury’s second annual Grand Rounds R&D meeting, which takes place next week in Chicago. This episode was sponsored by Jeito Capital.
View full story: https://www.biocentury.com/article/656038
#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment
00:01 - Sponsor Message: Jeito Capital
24:52 - HK IPOs
07:12 - ASCO
16:37 - EpCAM
20:16 - Rocket
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Reach us by sending a text
4.9
2828 ratings
Dutch biotech Merus’ EGFR x LGR5 bispecific antibody has caught investors’ attention in the run-up to ASCO as a new approach to block EGFR signaling. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Phase II data from Merus for petosemtamab as they preview the American Society of Clinical Oncology’s upcoming annual meeting. The analysts also assess a setback in a gene therapy trial for Rocket Pharmaceuticals, renewed interest in cancer target EpCAM, and a flurry of biopharma activity on the Hong Kong stock exchange. Finally, the team previews BioCentury’s second annual Grand Rounds R&D meeting, which takes place next week in Chicago. This episode was sponsored by Jeito Capital.
View full story: https://www.biocentury.com/article/656038
#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment
00:01 - Sponsor Message: Jeito Capital
24:52 - HK IPOs
07:12 - ASCO
16:37 - EpCAM
20:16 - Rocket
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Reach us by sending a text
752 Listeners
2,173 Listeners
39 Listeners
122 Listeners
318 Listeners
59 Listeners
88 Listeners
147 Listeners
10 Listeners
38 Listeners
155 Listeners
3 Listeners
11 Listeners
51 Listeners
11 Listeners